ID: h-665660604fa7
Hypothesis
Night-phase orexin receptor antagonism rescues AD by restoring sleep-dependent clearance
Timed OX1R/OX2R antagonism during the rest phase may consolidate sleep, improve glymphatic/interstitial clearance, and reduce amyloid or tau stress while avoiding daytime cognitive suppression.
EvidenceStrong (64%)📖 8 cit🗣 1 debates✓ 8 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Timed OX1R/OX2R antagonism during the rest phase may consolidate sleep, improve glymphatic/interstitial clearance, and reduce amyloid or tau stress while avoiding daytime cognitive suppression. The therapeutic effect should depend on circadian timing.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD A["Night-phase OX1R/OX2R Antagonism"] -->|"Restores sleep architecture"| B["Sleep Consolidation"] A -->|"Target: HCRTR2"| C["Orexin Signaling Suppression"] C -->|"Disinhibition of NREM sleep"| B B -->|"Enhances convective flow"| D["Glymphatic Clearance Activation"] D -->|"Increases ISF drainage"| E["Interstitial A-beta Reduction"] D -->|"Clears metabolite waste"| F["Tau Phosphorylation Decrease"] E -->|"Reduces seeding events"| F F -->|"Prevents neurofibrillary tangle formation"| G["Synaptic Protection"] A -->|"Avoids daytime orexin blockade"| H["Preserved Daytime Cognition"] G -->|"Maintains neuronal signaling"| I["Cognitive Function Rescue"] H -->|"No executive suppression"| I E -->|"Decreases amyloid plaque burden"| I G -->|"Prevents progressive neurodegeneration"| J["AD Pathology Attenuation"] I -->|"Clinical benefit"| K["Memory Improvement"] K -->|"Therapeutic outcome"| L["Disease Modification"]
⚖️ Evidence
⚖️ Evidence Matrix6 supports1 contradicts
Supports
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
Supports
Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease.
Supports
Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation.
Supports
Quantitative Assessment of Hippocampal Tau Pathology in AD and PART.
Supports
TDP-43 pathology is associated with increased tau burdens and seeding.
Contradicts
Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake transition and hemodynamic stability during propofol, dexmedetomidine, and remifentanil anesthesia.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — HCRTR2
No curated PDB or AlphaFold mapping for HCRTR2 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for HCRTR2 from GTEx v10.
💉 Clinical Trials (3)Relevance: 76%
0
Active
Active
0
Completed
Completed
0
Total Enrolled
Total Enrolled
PHASE2
Highest Phase
Highest Phase
RECRUITING·NCT05924425 · University Hospital, Montpellier
Alzheimer Disease Insomnia Disorder Sleep
Daridorexant 50 mg Placebo Polysomnography
RECRUITING·NCT07213349 · Douglas Mental Health University Institute
Alzheimer Disease (AD)
Daridorexant 50 mg Placebo
RECRUITING·NCT06274528 · Washington University School of Medicine
Alzheimer Disease
Lemborexant 10 mg Lemborexant 20mg Placebo
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HCRTR2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.8%
Volatility
Low
0.0099
Events (7d)
3
Price History
▼26.7%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.